A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children Between 30 Days and 18 Years of Age.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Abacavir; Amprenavir; Antiretrovirals; Atazanavir; Darunavir; Didanosine; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Fosamprenavir; HIV protease inhibitors; Indinavir; Lamivudine; Lamivudine/zidovudine; Lopinavir/ritonavir; Nelfinavir; Nevirapine; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zalcitabine; Zidovudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms PENPACT 1; PENTA 9
- 07 Feb 2019 Biomarkers information updated
- 27 Nov 2011 Additional trial centre and investigator identified as reported by United Kingdom Clinical Research Network record.
- 27 Nov 2011 New source identified and integrated (United Kingdom Clinical Research Network: 2322).